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During the past decade there has been extraordinary progress toward the development of
vaccines for the prevention of type A and type B hepatitis.
The successful propagation of hepatitis A virus in cell culture in 1979 was followed by the
preparation of experimental live attenuated hepatitis A vaccines that have been shown to in-
duce antibody in marmosets and chimpanzees and protect immunized marmosets against
challenge with hepatitis A virus. The first human immunization trials will begin in mid-1982.
An inactivated hepatitis B vaccine that was licensed in the United States in November 1981
has been shown to be safe, immunogenic, and effective. When this vaccine becomes available
for use in July 1982, it will be recommended for persons who are considered to be at increased
risk of contracting hepatitis B infection. Future generations of hepatitis B vaccines may be
prepared from hepatitis B surface antigen derived from DNA recombinant technology or by in
vitro synthesis of HBs Ag determinants by chemical means.
It was in 1947, 35 years ago, that Dorothy Horstmann and her colleagues de-
scribed two institutional outbreaks of infectious hepatitis, a disease that was formerly
called "acute catarrhal jaundice" [1]. Her study demonstrated that the disease was
relatively mild and of short duration in children as compared with adults. During
that same year MacCallum of Great Britain proposed that the term "type A
hepatitis" be designated for infectious hepatitis and "type B hepatitis" for serum
hepatitis.
Studies by various investigators during the 1940s and 1950s provided convincing
evidence of the existence of two immunologically distinct agents: hepatitis A virus
(HAV) and hepatitis B virus (HBV). However, all efforts to identify these agents or
to transmit them to animals were unsuccessful. In addition, attempts to propagate
these viruses in cell culture also ended in failure during the 1950s and 1960s. In spite
of these obstacles, progress toward the development of hepatitis A and B vaccines is
very encouraging. The first human trials with an experimental live attenuated
hepatitis A vaccine will begin in 1982. In addition, an inactivated hepatitis B vaccine
that was licensed in November 1981 will be available for use by July 1982.
The importance of hepatitis A and B as worldwide problems has been well
recognized for many years. These infections are major causes of acute and chronic
liver disease in developing and developed countries of the world.
VIRAL HEPATITIS IN DEVELOPING COUNTRIES
In general, type A hepatitis is a relatively benign disease in developing countries; it
usually occurs as an inapparent infection or mild illness, predominantly in infants
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All rights of reproduction in any form reserved.and children. Complications are rare, recovery is usually complete, and most adults
are immune. Consequently, there is no urgent need for a hepatitis A vaccine in these
areas.
In contrast, type B hepatitis is a more serious infection in children as well as
adults; it may be complicated by a chronic hepatitis B carrier state and by chronic
active hepatitis that may progress to cirrhosis and primary hepatocellular carcinoma
(PHC). The hepatitis B carrier rate in various Asian and African countries has ranged
between 10 percent and 20 percent, an indication of the severity and extent of
chronic liver disease in these areas. In these countries PHC is the most common type
of cancer, accounting for 20 percent to 40 percent of all malignant tumors. Conse-
quently, under the conditions existing in these countries, there is an urgent need for
an effective hepatitis B vaccine.
VIRAL HEPATITIS IN DEVELOPED COUNTRIES
The situation is strikingly different in most developed countries where
improvements in sanitation and hygiene have been associated with a declining in-
cidence of hepatitis A infection, especially in children. This phenomenon is respon-
sible for the corresponding increase in susceptibility of the adult population. For
example, today more than 60 percent of healthy adults in the United States are
susceptible to type A hepatitis. Since type A hepatitis is a moderately severe disease
in adults, there may be a need for a hepatitis A vaccine to protect those who travel to
highly endemic areas or are exposed to immigrants from endemic areas, especially in
schools, hospitals, refugee camps, institutions, and other crowded settings. A safe
and effective hepatitis B vaccine is needed for high-risk population groups in
developed as well as developing countries of the world. Various high-risk groups for
whom the vaccine is recommended will be described later.
HEPATITIS A VACCINE
The sequence of events that led to the development of an experimental live at-
tenuated hepatitis A vaccine began 15 years ago. In 1967 Deinhardt and colleagues
[2] reported the successful transmission of human HAV to marmoset monkeys.
These observations were subsequently confirmed by Mascoli and colleagues [3] and
other investigators. In 1973 Feinstone and colleagues [4] identified 27 mn virus-like
particles in stools obtained from patients with acute type A hepatitis. These particles
were initially identified by immune electronmicroscopy and later they were
characterized as RNA viruses closely related to the enterovirus family of agents
[5,6].
The availability of a specific antigen (HA Ag) led to the development of specific
tests for the identification of both the virus and its antibody (anti-HAV). These
serologic tests enabled investigators to identify susceptible chimpanzees, excellent
animals models for hepatitis A vaccine studies.
The crucial contribution that led to the development of a hepatitis A vaccine was
the successful propagation of human HAV in cell culture in vivo by Provost and
Hilleman in 1979 [7]. This important milestone was achieved 30 years after Enders,
Weller, and Robbins first cultivated poliovirus in cell culture [8].
Provost and Hilleman cultivated HAV in primary explant cell cultures of mar-
moset livers and in normal fetal rhesus kidney cell culture (FR K6). The virus
was identified by immunofluorescence, immunofluorescence blockade, serum
neutralization, immune adherence, radioimmunossay, immune electronmicros-
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copy, and marmoset inoculation tests. No cytopathology was observed. These
observations were confirmed and extended by Frosner, Deinhardt, and colleagues
[9], and by Purcell and colleagues [10]. The virus has been isolated directly from
human feces, and it has been propagated in a human diploid cell line.
During the course of a meeting of the U.S.-Japan hepatitis panel in March 1982,
Dr. Maurice Hilleman of Merck Institute for Therapeutic Research stated that "at-
tenuated live virus vaccines have been prepared that induce antibody in marmosets
and chimpanzees and protect marmosets against challenge infection." The initial
human immunization trials should begin by mid-1982.
HEPATITIS B VACCINE
The prerequisite for the development of poliovaccine, measles, mumps, rubella,
and hepatitis A vaccines was the successful cultivation of these agents in cell culture,
thereby providing the huge quantities of antigen required for vaccine production. To
date, no one has successfully propagated HBV in cell culture. Nevertheless, it has
been possible to develop a safe, immunogenic, and effective inactivated hepatitis B
vaccine.
The crucial milestone that led to the development of a hepatitis B vaccine was the
discovery of the Australia antigen by Blumberg and colleagues in 1965 [11], and its
subsequent association with HBV by Prince in 1968 [121. In 1970 and 1971 our
group reported that heat-inactivated serum containing our MS-2 strain of HBV was
immunogenic and partially protective [13]. Vaccine development was accelerated in
1973 when Barker and colleagues [14] successfully transmitted HBV to susceptible
chimpanzees. This excellent animal model proved to be valuable for evaluation of
safety, immunogenicity, and protective efficacy of the vaccine.
Our initial observation, that it was possible to prepare a crude hepatitis B vaccine
by the simple procedure of boiling a 1:10 dilution of MS-2 serum in distilled water,
was difficult to explain. Later, it became obvious that this unique, complex virus
had a surface component, the hepatitis B surface antigen (HBs Ag) that was im-
munologically distinct from the DNA containing core component, the hepatitis B
core antigen (HBc Ag). During the synthesis of HBV in infected hepatocytes, enor-
mous amounts ofexcess HBs Ag particles are formed and persist in the blood of per-
sons with chronic hepatitis B infection. The blood of hepatitis B carriers that con-
tains between 1010 and 1012 HBs Ag particles per ml has proved to be an excellent
source of antigen for vaccine production.
In 1975 Purcell and Gerin [15] and Hilleman and colleagues [16] described their
initial studies with an inactivated hepatitis B vaccine prepared from purified
preparations of HBs Ag. Since 1975 similar vaccines have been developed in France
[17], in Holland [18], in Japan, and in China [19]. The procedures involved in the
preparation of these subunit vaccines have been described in several publications
[15,16]. In general, the steps involve the collection of large quantities of HBs Ag-
positive plasma for purification of the HBs Ag particles by ammonium sulfate con-
centration, isopyknic banding on sodium bromide, rate zonal separation on a
sucrose gradient, and digestion with pepsin. A 1:4000 dilution of formaldehyde
solution is added to eliminate any potential residual live virus and the final product
is formulated in an alum adjuvant. The current licensed Merck vaccine (HEPTA-
VAX-B, Merck, Sharp & Dohme) contains 20 /tg of HBs Ag protein per ml.
The first human trials with the inactivated vaccine were initiated in 1975 after
safety, immunogenicity, and efficacy had been demonstrated in chimpanzees.
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licensure of inactivated hepatitis B vaccines in France and in the United States in
1981. The inactivated hepatitis B vaccine (HEPTAVAX-B, Merck, Sharp& Dohme)
that was licensed for use in the United States was evaluated for safety, im-
munogenicity, and efficacy in more than 6000 persons.
SAFETY
Clinical reactions in seronegative recipients of vaccine have been minimal and
transient. Mild local soreness at the site of inoculation has been the most common
side effect. Systemic reactions have been rare. During the course of placebo-
controlled, double-blind, randomized studies the incidence of side effects was essen-
tially the same in vaccine and placebo groups [20]. In general, the vaccine has been
extremely well tolerated.
IMMUNOGENICITY
In most studies optimum immunogenicity has been achieved by two inoculations
of inactivated hepatitis B vaccine given one month apart and followed by a booster
dose six months after the first dose. The anti-HBs response in immunocompetent
children and adults has ranged between 30 percent and 50 percent after the first
dose, 75 percent to 90 percent after the second dose, and over 95 percent after the
booster dose at six months. The vaccine has also proved to be highly immunogenic
for newborn infants [21,22]. Barin and colleagues [23] immunized 26 Senegalese in-
fants with three inoculations of vaccine containing 5 ,ug of HBs Ag per dose. The
vaccine, given before the babies were one month old, was well tolerated, and it in-
duced an anti-HBs response in 94.7 percent of infants whose prevaccination serum
contained no detectable HBs Ag or anti-HBs.
Vaccine-induced antibody has persisted for the three-year period of observation.
If these levels decline in the future, a subsequent booster dose will be required. It is
anticipated that vaccine-induced anti-HBs should persist for at least five years in
those vaccinees who had a good response.
Unfortunately, immunocompromised dialysis patients have not responded to the
vaccine as well as healthy adults. Studies to be published by Szmuness and col-
leagues have revealed an anti-HBs response of60 percent to 70 percent after three 40
,ug doses of heptatitis B vaccine.
EFFICACY
The efficacy ofinactivated hepatitis B vaccine was demonstrated by Szmuness and
colleagues [20,24] in a superbly designed and implemented placebo-controlled, ran-
domized clinical trial in a high-risk group ofmale homosexuals. Of 1083 volunteers,
549 received vaccine and 534 received placebo. The results of the study are sum-
marized in Table 1. As indicated in the report by Szmuness and colleagues [24] "the
attack rate of hepatitis B virus infections (excluding conversions of anti-HBc alone)
was 3.2% in vaccine recipients compared with 25.6% in placebo recipients (p
<0.0001). In those who received all three doses of40/g each, the protective efficacy
rate was 100o. The vaccine protected against acute hepatitis B, asymptomatic infec-
tion, and chronic antigenemia." Since 20 ,ug doses ofvaccine have been shown to be as
immunogenic as 40 /%g doses [25,26], and since the presence of anti-HBs has been
shown to be indicative of protection, it is reasonable to conclude that three 20 yg
doses of vaccine will be protective.
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TABLE 1
Attack Rates for Various Categories of Trial End Points in Placebo and Vaccine Recipients
Placebo Vaccine
Group Group Log-Rank P
End Point No. Rate No. Rate Chi-Square Value
Hepatitis B (ALT* 45 18.1 7 1.4 29.66 <0.0001
>90 IU only)
HBV events with 56 21.7 13 3.4 29.56 <0.0001
ALT >45 IU
All HBsAg-positive 70 24.4 11 3.0 48.63 <0.0001
events
All HBV events, 73 27.1 14 3.5 44.36 <0.0001
excluding conver-
sion to anti-HBc
alone
All HBV events, 93 35.0 29 7.6 38.77 <0.0001
including anti-HBc
conversions
*ALT = alanine aminotransferase (SGPT).
Source: Szmuness W et al.: N Engl J Med 303:833, 1980. Reprinted, by permission of the New
England Journal of Medicine.
RECOMMENDATION FOR USE OF HEPATITIS B VACCINE
The vaccine is recommended for the protection of infants, children, and adults
who are at a high risk of acquiring type B hepatitis [27]. The incidence of past
hepatitis B infection in the high-risk groups listed in Table 2 may range between 20
percent and 90 percent, a rate that is fivefold to 18-fold greater than the incidence in
such low-risk persons as healthy blood donors.
The decision to test for susceptibility or immunity before immunization will de-
pend predominantly on cost-benefit factors. It is estimated that three doses of vac-
cine will cost about 100 dollars. Therefore, it would be important to routinely
pretest male homosexuals and residents of institutions where hepatitis B infection is
highly endemic. For example, only 30 percent to 40 percent of male homosexuals
will be susceptible. Pretesting for presence of past infection will save the substantial
cost of immunizing 60 percent to 70 percent ofthose who are immune. As indicated
in Table 2, prevaccination testing is recommended for those groups that are in a very
high-risk category; it is optional for those in whom the risk is not as great. It should
be noted that studies by Dienstag and colleagues [28] have shown that immunization
of HBs Ag-positive carriers or immune persons is not associated with untoward side
effects.
PASSIVE-ACTIVE IMMUNIZATION
The use of combined passive immunization with hepatitis B immune globulin
(HBIG) and active immunization with inactivated hepatitis B vaccine has been
studied by Szmuness and colleagues [29]. They demonstrated that passively acquired
anti-HiBs did not inhibit an active immune response to the vaccine. Studies currently
in progress have been designed to evaluate the efficacy of passive-active immuniza-
tion for postexposure prophylaxis in infants born of mothers who are infectious
HBV carriers.
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TABLE 2
Recommendations for Use of Inactivated Hepatitis B Vaccine in High-Risk Groups
Dose of Prevaccination
High-Risk Group Vaccine,* Ag Testst
Health care personnel 20 Optional
Physicians and dentists
Nurses
Paramedical and paradental personnel
Laboratory technicians
Selected patients in hemodialysis and
hematology/oncology units 40 Recommended
Children with thalassemia and hemophilia 10-20 Recommended
Residents (clients) and staff of institutions
for the mentally handicapped and their
classroom contacts 20 Recommended
Household contacts of carriers 20 Recommended
Classroom contacts of carriers 20 Optional
Homosexually active males 20 Recommended
Prostitutes 20 Recommended
Users of illicit drugs 20 Recommended
Prisoners 20 Optional
Certain military personnel 20 Optional
Infants and young children in high-risk areas 10-20 Optional
*Two doses at a one-month interval and a third (booster) dose as six months.
tBsAg and anti-HBs or anti-HBc tests.
Source: Krugman S: JAMA 247:2012, 1982. Copyright 1982, American Medical Association.
FUTURE HEPATITIS B VACCINES
This first generation hepatitis B vaccine will be more expensve than other viral
vaccines because of the complex process involved in the purification of HBs Ag
prepared from human plasma that is purchased from chronic carriers. If large quan-
tities of HBs Ag can be derived from recombinant DNA technology or in vitro syn-
thesis of HBs Ag determinants by chemical means, future generations of vaccine
may be less costly. This goal and its eventual achievement will be essential in order to
meet the urgent needs of the developing nations of the world.
REFERENCES
1. Horstmann DM, Havens WP Jr, Deutsch J: Infectious hepatitis in childhood: A report of two insti-
tutional outbreaks and a comparison ofthe disease in adults and children. J Pediatr 30:381-387, 1947
2. Deinhardt F, Holmes AW, Capps RB, et al: Studies on the transmission of human viral hepatitis to
marmoset monkeys. I. Transmission of disease, serial passage and description of liver lesions. J Exp
Med 125:673-688, 1967
3. Mascoli CC, Ittensohn VM, Villarejos VM, et al: Recovery of hepatitis agents in the marmoset from
human cases occurring in Costa Rica. Proc Soc Exp Biol Med 142:276-282, 1973
4. Feinstone SM, Kapikian AZ, Purcell RH: Hepatitis A: Detection by immune electron microscopy of
a virus-like antigen associated with acute illness. Science 182:1026-1028, 1973
5. Provost PJ, Walanski BS, Miller WJ, et al: Physical, chemical and morphologic dimensions of
human hepatitis A virus strain CR326. Proc Soc Exp Biol Med 148:532-539, 1975
6. Siegl G, Frosner GG: Characterization and classification of virus particles associated with hepatitis
A. I. Size, density, and sedimentation. J Virol 26:48-53, 1978
7. Provost PJ, Hilleman MR: Propagation of human hepatitis A virus in cell culture in vitro. Proc Soc
Exp Biol 159:201-203, 1978
8. Enders JF, Weller T, Robbins F: Cultivation of the Lansing strain of poliomyelitis virus in cultures
of various human embryomic tissues. Science 109:85-87, 1949HEPATITIS VIRUS VACCINES 381
9. Frosner GG, Deinhardt F, Scheid R, et al: Propagation ofhuman hepatitis A virus in a hepatoma cell
line. Infection 7:303-305, 1979
10. Purcell RH: Viral hepatitis: Some unanswered questions and unfinished business. In Virus and Liver.
Edited by L. Bianchi, W Gerok, K Sickinger, GA Stalder. Lancaster, England, MTP Press Ltd, 1980,
pp 75-82
11. Blumberg BS, Alter HJ, Visnich S: A "new" antigen in leukemia sera. JAMA 191:541-546, 1965
12. Prince AM: An antigen detected in the blood during the incubation period of serum hepatitis. Proc
Natl Acad Sci USA 60:814-821, 1968
13. Krugman S, Giles JP, Hammond J: Viral hepatitis, type B (MS-2 strain): Studies on active im-
munization. JAMA 217:41-45, 1971
14. Barker LF, Chisari FV, McGrath PP, et al: Transmission of type B viral hepatitis to chimpanzees. J
Infect Dis 127:648-662, 1973
15. Purcell RH, Gerin JL: Hepatitis B subunit vaccine: A preliminary report of safety and efficacy tests
in chimpanzees. Am J Med Sci 270:395-399, 1975
16. Hilleman MR, Buynak EG, Roehm RR, et al: Purified and inactivated hepatitis B vaccine. Progress
report. Am J Med Sci 270:401-404, 1975
17. Maupas P, Goudeau A, Coursaget P, et al: Immunization of hepatitis B in man. Lancet i:1367-1370,
1976
18. Reesink HW, Brummelhuis HGJ, Van Elven EH, et al: The preparation and evaluation ofa hepatitis
B vaccine in the Netherlands. In Viral Hepatitis. Edited by GN Vyas, SN Cohen, R Schmid.
Philadelphia, PA, Franklin Institute Press, 1978, p 714
19. Tao CM, Huang TY, Feng PF, et al: A preliminary study on hepatitis B vaccine. Chin Med J (Engl)
4:101-110, 1978
20. Szmuness W, Stevens CE, Harley EJ, et al: Hepatitis B vaccine: Demonstration of efficacy in a con-
trolled clinical trial in a high risk population in the United States. N Engl J Med 303:833-841, 1980
21. Hilleman MR, Buynak EB, McAleer WJ, et al: Newer developments in human hepatitis vaccines. In
Perspectives in Virology Xl. Edited by M Pollard. New York, Alan R Liss, 1980, pp 219-247
22. Maupas P, Charon J-P, Barin F, et al: Efficacy of hepatitis B vaccine in prevention ofearly HBs Ag
carrier state in children: Controlled trials in an endemic area (Senegal). Lancet i:289-292, 1981
23. Barin F, Goudeau A, Denis F, et al: Immune response in neonates to hepatitis B vaccine. Lancet
i:251-253, 1982
24. Szmuness W, Stevens CE, Zang EA, et al: A controlled clinical trial of the efficacy ofthe hepatitis B
vaccine (Heptavax B): A final report. Hepatology 1:377-385, 1981
25. Krugman S, Holley JP Jr, Davidson M, et al: Immunogenic effect of inactivated hepatitis B vaccine:
Comparison of 20 jg and 40 itg doses. J Med Virol 8:119-121, 1981
26. Szmuness W, Stevens CE, Harley EJ, et al: The immune response of healthy adults to a reduced dose
of hepatitis B vaccine. J Med Virol 8:123-129, 1981
27. Krugman S: The newly licensed hepatitis B vaccine: Characteristics and indications for use. JAMA
247:2012-2015, 1982
28. Dienstag J, Stevens CE, Szmuness W, et al: Immunization ofchronic hepatitis B surface antigen car-
riers with hepatitis B vaccine. Hepatology 1:506, 1981
29. Szmuness W, Stevens CE, Oleszko WR, et al: Passive-active immunization against hepatitis B: Im-
munogenicity studies in adult Americans. Lancet i:575-577, 1981